A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
for Crohn's Disease
Drug: Risankizumab
11 locations incl. Phoenix
Sponsor: AbbVie
Sex: All·Age: 2 - 17
Code: NCT05995353·Phase 3·Recruiting